enVVeno Medical CEO presents at Virtual Investor “Why Now” on-demand conference

Reuters2026/08/27 13:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

enVVeno Medical CEO Robert Berman participated in Virtual Investor’s “Why Now” on-demand conference.
Presentation highlighted FDA IDE clearance for a U.S. pivotal study of enVVe, a non-surgical replacement venous valve for severe DVI.
TAVVE pivotal trial expected to start in Q4 2026, targeting about 230 patients across up to 40 U.S. sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

enVVeno Medical CEO presents at Virtual Investor “Why Now” on-demand conference

You may also like

Crypto prices